Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 18/20 | 0.51 |
| ▸ | AKR1C2 | P52895 | 18/20 | 0.51 |
| ▸ | AKR1C1 | Q04828 | 3/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.46 |
| ▸ | AKR1C4 | P17516 | 2/20 | 0.46 |
| ▸ | CPN1 | P15169 | 1/20 | 0.41 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2656910 | 0.84 | AKR1C3 (0.55) | AKR1C3AKR1C2AKR1C1PTGS1AKR1B10 | |
| SCHEMBL20943203 | 0.83 | AKR1C3 (0.51) | AKR1C3AKR1C2AKR1C1PTGS1AKR1B10 | |
| SCHEMBL1590117 | 0.82 | AKR1C3 (0.59) | AKR1C3AKR1C2AKR1C1PTGS1AKR1B10 | |
| SCHEMBL1590616 | 0.82 | AKR1C3 (0.50) | AKR1C3AKR1C2AKR1C1PTGS1AKR1B10 | |
| SCHEMBL11193984 | 0.81 | AKR1C3 (0.53) | AKR1C3AKR1C2AKR1C1PTGS1AKR1B10 | |
| SCHEMBL11192581 | 0.80 | AKR1C3 (0.54) | AKR1C3AKR1C2AKR1C1PTGS1AKR1B10 | |
| SCHEMBL5099274 | 0.80 | ALDH1A1 (0.60) | AKR1C3AKR1C2AKR1C1PTGS1AKR1B10 | |
| SCHEMBL28295994 | 0.78 | CYP3A4 (0.46) | PTGS1ADRA1A | |
| SCHEMBL1574429 | 0.78 | AKR1C3 (0.58) | AKR1C3AKR1C2AKR1C1PTGS1HTR1A | |
| SCHEMBL8092960 | 0.78 | AKR1C3 (0.60) | AKR1C3AKR1C2AKR1C1PTGS1AKR1B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110086921-A1 | Novel Polymorphic Forms of (4--2-Methylphenyl)Carbonyl]Amino}-3-Methylphenyl)Acetic Acid | GLAXO GROUP LIMITED (GB) | 2011-04-14 | — | — | US | disclosed |
| EP-2307351-A2 | NOVEL SALTS OF (4-{Ý(5-{Ý(3-CHLOROPHENYL)METHYL¨OXY}-2-METHYLPHENYL)CARBONYL¨AMINO}-3-METHYLPHENYL)ACETIC ACID | Glaxo Group Limited (GB) | 2011-04-13 | — | — | EP | disclosed |
| US-20110082209-A1 | Novel Salts of (4--2-Methylphenyl)Carbonyl]Amino}-3-Methylphenyl)Acetic Acid | GLAXO GROUP LIMITED (GB) | 2011-04-07 | — | — | US | disclosed |
| EP-2303832-A1 | NOVEL POLYMORPHIC FORMS OF (4-{[(5-{[(3-CHLOROPHENYL)METHYL]OXY}-2-METHYLPHENYL)CARBONYL]AMINO}-3-METHYLPHENYL)ACETIC ACID | Glaxo Group Limited (GB) | 2011-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082209-A1 | Novel Salts of (4--2-Methylphenyl)Carbonyl]Amino}-3-Methylphenyl)Acetic Acid | ACMSD, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ACACA | AKR1C3 523/4885AKR1C2 320/4885AKR1C1 752/4885 |
| US-20110086921-A1 | Novel Polymorphic Forms of (4--2-Methylphenyl)Carbonyl]Amino}-3-Methylphenyl)Acetic Acid | CYP3A43, HLA-DRB1, UGT1A3 | AKR1C3 62/4885AKR1C2 56/4885AKR1C1 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.